English

Aligos Therapeutics, Inc.

EDGAR

ALGS Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about USD 2.186M, using the latest reported figures. The previous period, 2024, was about USD 3.611M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-25 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -48078000 USD Source
Operating Cash Flow: -23128000 USD Source

Cash and cash equivalents: 30.4 million USD 2026-06-30 Source
Exact value

30400000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 6.24 million shares 2026-06-30 Source
Exact value

6236828 shares

Reported share-count change

1.39% · 85.6 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

6151274 shares · 2025-06-30· Source
6236828 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

3.74 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 741000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 2186000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 2017000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 2830000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 0 USD · 2026-04-01 – 2026-06-30 Source

Net income

-76 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -31537000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -24193000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -4312000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -23040000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -1504000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-94.2 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -60758000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -36413000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -82503000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -60758000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -23128000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -48078000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -23128000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

435 thousand USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Capital expenditure: 849000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 515000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 852000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 849000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 943000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 852000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 7000 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2024-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-39.5%

Prior period

USD 3.61 million

2024-01-01 – 2024-12-31
Current period

USD 2.19 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2186000 − 3611000 = -1425000 USD

3611000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2186000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Aligos Therapeutics, Inc. · 2025-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Year-over-year change in Revenue: -1425000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 2186000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#3176382 Filing: 000119312526092614 Input fundies:Revenue: 3611000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#3178041 Filing: 000119312526092614
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 107.02 million

Prior period

−USD 131.21 million

2024-01-01 – 2024-12-31
Current period

−USD 24.19 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-24193000 − -131211000 = 107018000 USD

-131211000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-24193000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Aligos Therapeutics, Inc. · 2025-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Year-over-year change in Net income: 107018000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -24193000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#3215945 Filing: 000119312526092614 Input fundies:NetIncome: -131211000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#3217838 Filing: 000119312526092614
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.76 million

Prior period

−USD 80.74 million

2024-01-01 – 2024-12-31
Current period

−USD 82.5 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-82503000 − -80743000 = -1760000 USD

-80743000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-82503000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Aligos Therapeutics, Inc. · 2025-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Year-over-year change in Operating cash flow: -1760000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -82503000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#1995184 Filing: 000119312526092614 Input fundies:OperatingCashFlow: -80743000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#1997073 Filing: 000119312526092614
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 2.19 million 100% of revenue
Operating costs Derived USD 90.17 million 4,125% of revenue
Operating income −USD 87.99 million −4,025% of revenue
Tax, interest and other Derived −USD 63.79 million −2,918% of revenue
Net income −USD 24.19 million −1,107% of revenue

Cash

Operating cash flow −USD 82.5 million −3,774% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Operating loss: operating costs were 1,523% of revenue.
2024 Operating loss: operating costs were 2,569% of revenue.
2025 Operating loss: operating costs were 4,125% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	0	97834000 Derived	-97834000	10709000 Derived	-108543000	-76327000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -97834000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -108543000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -74263000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 2064000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	0	128321000 Derived	-128321000	11000 Derived	-128332000	-116554000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -128321000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -128332000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -115662000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 892000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	0	97580000 Derived	-97580000	-1534000 Derived	-96046000	-80332000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -97580000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -96046000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -79389000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 943000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	6191000	94318000 Derived	-88127000	-448000 Derived	-87679000	-79016000 Derived	Source 2023-01-01 – 2023-12-31: 6191000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -88127000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -87679000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -78997000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 19000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	3611000	92765000 Derived	-89154000	42057000 Derived	-131211000	-80873000 Derived	Source 2024-01-01 – 2024-12-31: 3611000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -89154000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -131211000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -80743000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 130000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	2186000	90171000 Derived	-87985000	-63792000 Derived	-24193000	Unavailable	Source 2025-01-01 – 2025-12-31: 2186000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -87985000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -24193000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -82503000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	0	Revenue: 0 Open source
20222022-12-31	Revenue	0	Revenue: 0 Open source
20232023-12-31	Revenue	6191000	Revenue: 6191000 Open source
20242024-12-31	Revenue	3611000	Revenue: 3611000 Open source
20252025-12-31	Revenue	2186000	Revenue: 2186000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-39.5% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 6191000 Open source Revenue: 0 Open source
20242024-12-31	Year over year	-41.7%	Revenue: 3611000 Open source Revenue: 6191000 Open source
20252025-12-31	Year over year	-39.5%	Revenue: 2186000 Open source Revenue: 3611000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4,024.9% 2025

Net margin -1,106.7% 2025

Free cash flow margin -2,239.6% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -97834000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -128321000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -97580000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	-1,423.5%	Operating Income: -88127000 Open source Revenue: 6191000 Open source
20242024-12-31	Operating margin	-2,469%	Operating Income: -89154000 Open source Revenue: 3611000 Open source
20252025-12-31	Operating margin	-4,024.9%	Operating Income: -87985000 Open source Revenue: 2186000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -108543000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -128332000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -96046000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	-1,416.2%	Net Income: -87679000 Open source Revenue: 6191000 Open source
20242024-12-31	Net margin	-3,633.6%	Net Income: -131211000 Open source Revenue: 3611000 Open source
20252025-12-31	Net margin	-1,106.7%	Net Income: -24193000 Open source Revenue: 2186000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -74263000 Open source Capital Expenditure: 2064000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -115662000 Open source Capital Expenditure: 892000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -79389000 Open source Capital Expenditure: 943000 Open source
20232023-12-31	Free cash flow margin	-1,276.3%	Revenue: 6191000 Open source Operating Cash Flow: -78997000 Open source Capital Expenditure: 19000 Open source
20242024-12-31	Free cash flow margin	-2,239.6%	Revenue: 3611000 Open source Operating Cash Flow: -80743000 Open source Capital Expenditure: 130000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 2186000 Open source Operating Cash Flow: -82503000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -82.5M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-74263000	Operating Cash Flow: -74263000 Open source
20212021-12-31	Operating cash flow	-115662000	Operating Cash Flow: -115662000 Open source
20222022-12-31	Operating cash flow	-79389000	Operating Cash Flow: -79389000 Open source
20232023-12-31	Operating cash flow	-78997000	Operating Cash Flow: -78997000 Open source
20242024-12-31	Operating cash flow	-80743000	Operating Cash Flow: -80743000 Open source
20252025-12-31	Operating cash flow	-82503000	Operating Cash Flow: -82503000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -80.9M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-76327000	Operating Cash Flow: -74263000 Open source Capital Expenditure: 2064000 Open source
20212021-12-31	Free cash flow	-116554000	Operating Cash Flow: -115662000 Open source Capital Expenditure: 892000 Open source
20222022-12-31	Free cash flow	-80332000	Operating Cash Flow: -79389000 Open source Capital Expenditure: 943000 Open source
20232023-12-31	Free cash flow	-79016000	Operating Cash Flow: -78997000 Open source Capital Expenditure: 19000 Open source
20242024-12-31	Free cash flow	-80873000	Operating Cash Flow: -80743000 Open source Capital Expenditure: 130000 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -82503000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

39.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	17.1%	Total Liabilities: 45263000 Open source Total Assets: 265302000 Open source
20212021-12-31	Liabilities / assets	21.5%	Total Liabilities: 50638000 Open source Total Assets: 235369000 Open source
20222022-12-31	Liabilities / assets	29.2%	Total Liabilities: 42793000 Open source Total Assets: 146693000 Open source
20232023-12-31	Liabilities / assets	39.2%	Total Liabilities: 59447000 Open source Total Assets: 151527000 Open source
20242024-12-31	Liabilities / assets	141.3%	Total Liabilities: 99067000 Open source Total Assets: 70094000 Open source
20252025-12-31	Liabilities / assets	39.5%	Total Liabilities: 34988000 Open source Total Assets: 88533000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.9× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	8.26×	Current Assets: 250017000 Open source Current Liabilities: 30274000 Open source
20212021-12-31	Current assets / current liabilities	5.25×	Current Assets: 204424000 Open source Current Liabilities: 38957000 Open source
20222022-12-31	Current assets / current liabilities	4.03×	Current Assets: 133545000 Open source Current Liabilities: 33129000 Open source
20232023-12-31	Current assets / current liabilities	5.9×	Current Assets: 141084000 Open source Current Liabilities: 23906000 Open source
20242024-12-31	Current assets / current liabilities	2.86×	Current Assets: 62141000 Open source Current Liabilities: 21737000 Open source
20252025-12-31	Current assets / current liabilities	3.9×	Current Assets: 82862000 Open source Current Liabilities: 21233000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 52.26 million Exact value Exact value: -52264000 USD 2019-01-01 – 2019-12-31: -52264000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aligos Therapeutics, Inc. · 2019-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Net Income: -52264000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52264000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000156459021014872/algs-20201231.xml#187179 Filing: 000156459021014872 The citation records this snapshot. The page link may show a newer release later.	−USD 46.77 million Exact value Exact value: -46767000 USD 2019-01-01 – 2019-12-31: -46767000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aligos Therapeutics, Inc. · 2019-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Operating Cash Flow: -46767000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -46767000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000156459021014872/algs-20201231.xml#213875 Filing: 000156459021014872 The citation records this snapshot. The page link may show a newer release later.	USD 2.79 million Exact value Exact value: 2786000 USD 2019-01-01 – 2019-12-31: 2786000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aligos Therapeutics, Inc. · 2019-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Capital Expenditure: 2786000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2786000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000156459021014872/algs-20201231.xml#215587 Filing: 000156459021014872 The citation records this snapshot. The page link may show a newer release later.	−USD 49.55 million Calculation and evidence -46767000 − 2786000 USD Exact free cash flow: -49553000 USD 2019-01-01 – 2019-12-31: -46767000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2786000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aligos Therapeutics, Inc. · 2019-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Free cash flow: -49553000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -46767000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000156459021014872/algs-20201231.xml#213875 Filing: 000156459021014872 Input fundies:CapitalExpenditure: 2786000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000156459021014872/algs-20201231.xml#215587 Filing: 000156459021014872 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 108.54 million Exact value Exact value: -108543000 USD 2020-01-01 – 2020-12-31: -108543000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aligos Therapeutics, Inc. · 2020-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Net Income: -108543000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -108543000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017022003365/algs-20211231.htm#3723288 Filing: 000095017022003365 The citation records this snapshot. The page link may show a newer release later.	−USD 74.26 million Exact value Exact value: -74263000 USD 2020-01-01 – 2020-12-31: -74263000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aligos Therapeutics, Inc. · 2020-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Operating Cash Flow: -74263000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -74263000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017022003365/algs-20211231.htm#2356408 Filing: 000095017022003365 The citation records this snapshot. The page link may show a newer release later.	USD 2.06 million Exact value Exact value: 2064000 USD 2020-01-01 – 2020-12-31: 2064000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aligos Therapeutics, Inc. · 2020-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Capital Expenditure: 2064000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2064000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017022003365/algs-20211231.htm#2378643 Filing: 000095017022003365 The citation records this snapshot. The page link may show a newer release later.	−USD 76.33 million Calculation and evidence -74263000 − 2064000 USD Exact free cash flow: -76327000 USD 2020-01-01 – 2020-12-31: -74263000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2064000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aligos Therapeutics, Inc. · 2020-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Free cash flow: -76327000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -74263000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017022003365/algs-20211231.htm#2356408 Filing: 000095017022003365 Input fundies:CapitalExpenditure: 2064000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017022003365/algs-20211231.htm#2378643 Filing: 000095017022003365 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 128.33 million Exact value Exact value: -128332000 USD 2021-01-01 – 2021-12-31: -128332000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aligos Therapeutics, Inc. · 2021-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Net Income: -128332000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -128332000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017023007033/algs-20221231.htm#3572632 Filing: 000095017023007033 The citation records this snapshot. The page link may show a newer release later.	−USD 115.66 million Exact value Exact value: -115662000 USD 2021-01-01 – 2021-12-31: -115662000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aligos Therapeutics, Inc. · 2021-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Operating Cash Flow: -115662000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -115662000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017023007033/algs-20221231.htm#2173461 Filing: 000095017023007033 The citation records this snapshot. The page link may show a newer release later.	USD 892,000 Exact value Exact value: 892000 USD 2021-01-01 – 2021-12-31: 892000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aligos Therapeutics, Inc. · 2021-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Capital Expenditure: 892000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 892000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017023007033/algs-20221231.htm#2197471 Filing: 000095017023007033 The citation records this snapshot. The page link may show a newer release later.	−USD 116.55 million Calculation and evidence -115662000 − 892000 USD Exact free cash flow: -116554000 USD 2021-01-01 – 2021-12-31: -115662000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 892000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aligos Therapeutics, Inc. · 2021-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Free cash flow: -116554000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -115662000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017023007033/algs-20221231.htm#2173461 Filing: 000095017023007033 Input fundies:CapitalExpenditure: 892000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017023007033/algs-20221231.htm#2197471 Filing: 000095017023007033 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 96.05 million Exact value Exact value: -96046000 USD 2022-01-01 – 2022-12-31: -96046000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aligos Therapeutics, Inc. · 2022-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Net Income: -96046000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -96046000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017024029953/algs-20231231.htm#2692018 Filing: 000095017024029953 The citation records this snapshot. The page link may show a newer release later.	−USD 79.39 million Exact value Exact value: -79389000 USD 2022-01-01 – 2022-12-31: -79389000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aligos Therapeutics, Inc. · 2022-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Operating Cash Flow: -79389000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -79389000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017024029953/algs-20231231.htm#1723614 Filing: 000095017024029953 The citation records this snapshot. The page link may show a newer release later.	USD 943,000 Exact value Exact value: 943000 USD 2022-01-01 – 2022-12-31: 943000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aligos Therapeutics, Inc. · 2022-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Capital Expenditure: 943000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 943000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017024029953/algs-20231231.htm#1736352 Filing: 000095017024029953 The citation records this snapshot. The page link may show a newer release later.	−USD 80.33 million Calculation and evidence -79389000 − 943000 USD Exact free cash flow: -80332000 USD 2022-01-01 – 2022-12-31: -79389000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 943000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aligos Therapeutics, Inc. · 2022-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Free cash flow: -80332000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -79389000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017024029953/algs-20231231.htm#1723614 Filing: 000095017024029953 Input fundies:CapitalExpenditure: 943000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017024029953/algs-20231231.htm#1736352 Filing: 000095017024029953 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 87.68 million Exact value Exact value: -87679000 USD 2023-01-01 – 2023-12-31: -87679000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aligos Therapeutics, Inc. · 2023-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Net Income: -87679000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -87679000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017025035929/algs-20241231.htm#3117313 Filing: 000095017025035929 The citation records this snapshot. The page link may show a newer release later.	−USD 79 million Exact value Exact value: -78997000 USD 2023-01-01 – 2023-12-31: -78997000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aligos Therapeutics, Inc. · 2023-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Operating Cash Flow: -78997000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -78997000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017025035929/algs-20241231.htm#1900737 Filing: 000095017025035929 The citation records this snapshot. The page link may show a newer release later.	USD 19,000 Exact value Exact value: 19000 USD 2023-01-01 – 2023-12-31: 19000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aligos Therapeutics, Inc. · 2023-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Capital Expenditure: 19000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017025035929/algs-20241231.htm#1916705 Filing: 000095017025035929 The citation records this snapshot. The page link may show a newer release later.	−USD 79.02 million Calculation and evidence -78997000 − 19000 USD Exact free cash flow: -79016000 USD 2023-01-01 – 2023-12-31: -78997000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 19000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aligos Therapeutics, Inc. · 2023-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Free cash flow: -79016000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -78997000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017025035929/algs-20241231.htm#1900737 Filing: 000095017025035929 Input fundies:CapitalExpenditure: 19000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017025035929/algs-20241231.htm#1916705 Filing: 000095017025035929 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 131.21 million Exact value Exact value: -131211000 USD 2024-01-01 – 2024-12-31: -131211000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aligos Therapeutics, Inc. · 2024-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Net Income: -131211000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -131211000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#3217838 Filing: 000119312526092614 The citation records this snapshot. The page link may show a newer release later.	−USD 80.74 million Exact value Exact value: -80743000 USD 2024-01-01 – 2024-12-31: -80743000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aligos Therapeutics, Inc. · 2024-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Operating Cash Flow: -80743000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -80743000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#1997073 Filing: 000119312526092614 The citation records this snapshot. The page link may show a newer release later.	USD 130,000 Exact value Exact value: 130000 USD 2024-01-01 – 2024-12-31: 130000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aligos Therapeutics, Inc. · 2024-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Capital Expenditure: 130000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 130000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017025035929/algs-20241231.htm#1914948 Filing: 000095017025035929 The citation records this snapshot. The page link may show a newer release later.	−USD 80.87 million Calculation and evidence -80743000 − 130000 USD Exact free cash flow: -80873000 USD 2024-01-01 – 2024-12-31: -80743000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 130000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aligos Therapeutics, Inc. · 2024-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Free cash flow: -80873000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -80743000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#1997073 Filing: 000119312526092614 Input fundies:CapitalExpenditure: 130000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000095017025035929/algs-20241231.htm#1914948 Filing: 000095017025035929 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 24.19 million Exact value Exact value: -24193000 USD 2025-01-01 – 2025-12-31: -24193000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aligos Therapeutics, Inc. · 2025-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Net Income: -24193000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24193000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#3215945 Filing: 000119312526092614 The citation records this snapshot. The page link may show a newer release later.	−USD 82.5 million Exact value Exact value: -82503000 USD 2025-01-01 – 2025-12-31: -82503000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aligos Therapeutics, Inc. · 2025-12-31 Aligos Therapeutics, Inc. (edgar:1799448) Operating Cash Flow: -82503000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:40:56Z Snapshot: ba2bc71d3143c8edb8d74c2c9b6cd2abf02b2ef3670761bfee653929655bbfb4 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1799448/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -82503000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/algs-20251231.htm#1995184 Filing: 000119312526092614 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

32 filings · 1,558 latest values · 1,558 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001799448, 1799448, ALGS, edgar:1799448

Also known as Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation